Biohub AI Protein Model Launch Accelerates Drug Discovery

Biohub, the research initiative funded by Mark Zuckerberg and Priscilla Chan, unveiled an open‑source AI‑driven “world model” for protein design. Built on fourth‑generation evolutionary scale modelling, the system learns patterns from billions of protein sequences to predict structures and suggest new designs, aiming to speed early‑stage drug discovery. Early tests have produced protein binders that reactivate immune cells, indicating potential for cancer and immune‑disease therapies.

In related biotech developments, the U.S. FDA has postponed its decision on AstraZeneca’s experimental breast‑cancer drug camizestrant to allow further data review, while Blackstone Life Sciences pledged up to $1.3 billion to support Apogee Therapeutics’ Phase 3 trial of an atopic dermatitis treatment. Additionally, Kailera reported that its investigational “triple‑G” obesity drug, which targets three hormones, achieved significant weight loss in a Phase 1 study.